While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the Swiss drugmaker is happy to sit this round out. | While Big Pharmas embarked on a frenzy of acquisitions over recent weeks,

With the purchase of Organon & Co., billionaire Dilip Shanghvi's Sun Pharmaceutical Industries' annual revenue will more than double to $12.4 billion and make it one of the world’s top 25 drugmakers.

A judge has rescheduled a hearing in which she is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the U.S. government. U.S.

AI tools that slash time spent on administration prove their worth and free up pharma workers for higher value tasks.

Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.

Welcome to the Sun Pharma Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent stocks in the market. Stay on top of the game with our comprehensive coverage,

By Puyaan Singh April 27 (Reuters) - Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday. The deal adds more than 120 treatments,

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Ascendis Pharma A/S (NASDAQ:ASND) ranks 9th on this list. The primary catalyst for hedge fund interest in Ascendis Pharma A/S (NASDAQ:ASND) stock over the past few weeks is the FDA approval of YUVIWEL for children with achondroplasia.